Lupin To Present Cancer Drug Data at ASCO 2025
ECONOMY & POLICY

Lupin To Present Cancer Drug Data at ASCO 2025

Global pharmaceutical firm Lupin Limited will present results from its Phase 1a clinical trial of LNP7457—a novel PRMT5 inhibitor—at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from 30 May to 3 June 2025. The data will be showcased during the Developmental Therapeutics—Molecularly Targeted Agents and Tumour Biology session on 2 June, between 1:30 pm and 4:30 pm (CDT), at Poster Board #422.

LNP7457 is a SAM-competitive PRMT5 inhibitor being developed for monotherapy in patients with advanced or metastatic solid tumours. According to trial findings, the drug has shown a favourable safety and tolerability profile, with pharmacokinetic/pharmacodynamic (PK/PD) data supporting further development. Food intake was found to have no impact on drug metabolism.

The maximum tolerated dose and the recommended Phase 2 dose were established based on cumulative safety, PK/PD, and efficacy data, and are consistent with preclinical models and existing safety profiles of PRMT5 inhibitors.

Vinita Gupta, CEO of Lupin, commented, “We are pleased to share encouraging data from our Phase I trial. LNP7457 represents a novel epigenetic therapeutic with significant promise, and reinforces our commitment to advancing innovative treatments for cancers with limited options.”

Lupin has already commenced its Phase 1b trial in India and aims to further evaluate LNP7457 for various oncology indications where unmet clinical needs persist.

Presentation Details:
4. Date: 2 June 2025
5. Time: 1:30–4:30 pm CDT
6. Location: Hall A, McCormick Place, Chicago
7. Abstract No.: 3107 | Poster Board No.: 422
8. Trial Registration: CTRI/2023/07/054753
9. DOI: 10.1200/JCO.2025.43.16_suppl.3107

Lupin’s participation at ASCO underscores its focus on precision oncology and its ambitions in the field of targeted cancer therapies.

Global pharmaceutical firm Lupin Limited will present results from its Phase 1a clinical trial of LNP7457—a novel PRMT5 inhibitor—at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from 30 May to 3 June 2025. The data will be showcased during the Developmental Therapeutics—Molecularly Targeted Agents and Tumour Biology session on 2 June, between 1:30 pm and 4:30 pm (CDT), at Poster Board #422.LNP7457 is a SAM-competitive PRMT5 inhibitor being developed for monotherapy in patients with advanced or metastatic solid tumours. According to trial findings, the drug has shown a favourable safety and tolerability profile, with pharmacokinetic/pharmacodynamic (PK/PD) data supporting further development. Food intake was found to have no impact on drug metabolism.The maximum tolerated dose and the recommended Phase 2 dose were established based on cumulative safety, PK/PD, and efficacy data, and are consistent with preclinical models and existing safety profiles of PRMT5 inhibitors.Vinita Gupta, CEO of Lupin, commented, “We are pleased to share encouraging data from our Phase I trial. LNP7457 represents a novel epigenetic therapeutic with significant promise, and reinforces our commitment to advancing innovative treatments for cancers with limited options.”Lupin has already commenced its Phase 1b trial in India and aims to further evaluate LNP7457 for various oncology indications where unmet clinical needs persist.Presentation Details:4. Date: 2 June 20255. Time: 1:30–4:30 pm CDT6. Location: Hall A, McCormick Place, Chicago7. Abstract No.: 3107 | Poster Board No.: 4228. Trial Registration: CTRI/2023/07/0547539. DOI: 10.1200/JCO.2025.43.16_suppl.3107Lupin’s participation at ASCO underscores its focus on precision oncology and its ambitions in the field of targeted cancer therapies.

Next Story
Infrastructure Transport

PM to Inaugurate Indore Metro Phase 1 and Datia Satna Airports on May 31

Prime Minister Narendra Modi is scheduled to inaugurate the first phase of the Indore Metro Rail project, along with the Datia and Satna airports, via video conferencing during his visit to Bhopal on May 31, according to a senior Madhya Pradesh cabinet official.During his day-long visit to Bhopal, the Prime Minister will also participate in a conference organized to commemorate the 300th birth anniversary of Devi Ahilyabai Holkar, the historic queen of the Malwa kingdom, now part of Madhya Pradesh, as stated by the Parliamentary Affairs Minister and Cabinet spokesperson Kailash Vijayvargiya.It..

Next Story
Infrastructure Transport

Kochi Metro Holds Talks with BPCL to Restore Greenery on Medians

Kochi Metro Rail (KMRL), facing increasing criticism for not maintaining the green spaces along the medians in the metro corridor, has initiated discussions with Bharat Petroleum Corporation (BPCL) and the Ernakulam District Horticulture Society to revive the project.Sources reveal that KMRL is also making fresh efforts to find sponsors to care for and maintain the gardens located between the metro pillars. Previously, several sponsors had withdrawn, which led to the neglect of these green areas.There are 989 medians along the 28-km Kochi Metro stretch. Of these, 465 are under the National Hig..

Next Story
Infrastructure Transport

Rajasthan CM Approves DPR for Jaipur Metro Phase-2 Expansion

Rajasthan Chief Minister Bhajanlal Sharma approved the detailed project report (DPR) of Jaipur Metro Phase-2 and forwarded it to the Central Government.The construction work for the project is set to begin once the Union Ministry of Housing and Urban Affairs grants approval to the DPR.Phase 2 of Jaipur Metro had been announced in the state budget for 2025-26.The project, covering a 42.80-km stretch from Todi Mode to Prahladpura, will be implemented by the Rajasthan Metro Rail Corporation—a newly formed 50:50 joint venture between the state and Central governments. The corporation will be res..

Advertisement

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Advertisement

Talk to us?